Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106


Correction: A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.

Qin T, Barron L, Xia L, Huang H, Villarreal MM, Zwaagstra J, Collins C, Yang J, Zwieb C, Kodali R, Hinck CS, Kim SK, Reddick RL, Shu C, O'Connor-McCourt MD, Hinck AP, Sun LZ.

Oncotarget. 2017 Aug 21;8(34):57905. doi: 10.18632/oncotarget.20370. eCollection 2017 Aug 22.


Assisted Design of Antibody and Protein Therapeutics (ADAPT).

Vivcharuk V, Baardsnes J, Deprez C, Sulea T, Jaramillo M, Corbeil CR, Mullick A, Magoon J, Marcil A, Durocher Y, O'Connor-McCourt MD, Purisima EO.

PLoS One. 2017 Jul 27;12(7):e0181490. doi: 10.1371/journal.pone.0181490. eCollection 2017.


Correction to Binding Properties of the Transforming Growth Factor-β Coreceptor Betaglycan: Proposed Mechanism for Potentiation of Receptor Complex Assembly and Signaling.

Villarreal MM, Kim SK, Barron L, Kodali R, Baardsnes J, Hinck CS, Krzysiak TC, Henen MA, Pakhomova O, Mendoza V, O'Connor-McCourt MD, Lafer EM, López-Casillas F, Hinck AP.

Biochemistry. 2017 Jul 18;56(28):3689. doi: 10.1021/acs.biochem.7b00566. Epub 2017 Jul 5. No abstract available.


Binding Properties of the Transforming Growth Factor-β Coreceptor Betaglycan: Proposed Mechanism for Potentiation of Receptor Complex Assembly and Signaling.

Villarreal MM, Kim SK, Barron L, Kodali R, Baardsnes J, Hinck CS, Krzysiak TC, Henen MA, Pakhomova O, Mendoza V, O'Connor-McCourt MD, Lafer EM, López-Casillas F, Hinck AP.

Biochemistry. 2016 Dec 13;55(49):6880-6896. Epub 2016 Dec 2. Erratum in: Biochemistry. 2017 Jul 18;56(28):3689.


A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.

Qin T, Barron L, Xia L, Huang H, Villarreal MM, Zwaagstra J, Collins C, Yang J, Zwieb C, Kodali R, Hinck CS, Kim SK, Reddick RL, Shu C, O'Connor-McCourt MD, Hinck AP, Sun LZ.

Oncotarget. 2016 Dec 27;7(52):86087-86102. doi: 10.18632/oncotarget.13343. Erratum in: Oncotarget. 2017 Aug 21;8(34):57905.


Computational selection of antibody-drug conjugate targets for breast cancer.

Fauteux F, Hill JJ, Jaramillo ML, Pan Y, Phan S, Famili F, O'Connor-McCourt M.

Oncotarget. 2016 Jan 19;7(3):2555-71. doi: 10.18632/oncotarget.6679.


Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M, Wang E.

JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413.


Glycoproteomic comparison of clinical triple-negative and luminal breast tumors.

Hill JJ, Tremblay TL, Fauteux F, Li J, Wang E, Aguilar-Mahecha A, Basik M, O'Connor-McCourt M.

J Proteome Res. 2015 Mar 6;14(3):1376-88. doi: 10.1021/pr500987r. Epub 2015 Feb 16.


Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.

Wang E, Zaman N, Mcgee S, Milanese JS, Masoudi-Nejad A, O'Connor-McCourt M.

Semin Cancer Biol. 2015 Feb;30:4-12. doi: 10.1016/j.semcancer.2014.04.002. Epub 2014 Apr 18. Review.


Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

Cruz-Muñoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O'Connor-McCourt MD, Kerbel RS.

Angiogenesis. 2014 Jul;17(3):661-73. doi: 10.1007/s10456-014-9422-9. Epub 2014 Feb 26.


Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets.

Zaman N, Li L, Jaramillo ML, Sun Z, Tibiche C, Banville M, Collins C, Trifiro M, Paliouras M, Nantel A, O'Connor-McCourt M, Wang E.

Cell Rep. 2013 Oct 17;5(1):216-23. doi: 10.1016/j.celrep.2013.08.028. Epub 2013 Sep 26.


IGFBP-4 anti-angiogenic and anti-tumorigenic effects are associated with anti-cathepsin B activity.

Moreno MJ, Ball M, Rukhlova M, Slinn J, L'abbe D, Iqbal U, Monette R, Hagedorn M, O'Connor-McCourt MD, Durocher Y, Stanimirovic DB.

Neoplasia. 2013 May;15(5):554-67.


A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer.

Cohen A, Wang E, Chisholm KA, Kostyleva R, O'Connor-McCourt M, Pinto DM.

J Proteomics. 2013 Apr 9;81:135-47. doi: 10.1016/j.jprot.2012.11.004. Epub 2012 Nov 20.


Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.

Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS.

Cancer Res. 2012 Oct 1;72(19):4909-19. doi: 10.1158/0008-5472.CAN-12-2194. Epub 2012 Aug 3.


Engineering and therapeutic application of single-chain bivalent TGF-β family traps.

Zwaagstra JC, Sulea T, Baardsnes J, Lenferink AE, Collins C, Cantin C, Paul-Roc B, Grothe S, Hossain S, Richer LP, L'Abbé D, Tom R, Cass B, Durocher Y, O'Connor-McCourt MD.

Mol Cancer Ther. 2012 Jul;11(7):1477-87. doi: 10.1158/1535-7163.MCT-12-0060. Epub 2012 May 4.


Molecular imaging of breast tumors using a near-infrared fluorescently labeled clusterin binding peptide.

Filfil R, Paul-Roc B, Cantin C, Iqbal U, Tolkatchev D, Vinogradova A, Xu P, Ni F, O'Connor-McCourt MD, Lenferink AE.

Int J Cancer. 2012 Sep 1;131(5):E681-92. doi: 10.1002/ijc.27368. Epub 2012 Jan 27.


Structures of TGF-β receptor complexes: implications for function and therapeutic intervention using ligand traps.

Hinck AP, O'Connor-McCourt MD.

Curr Pharm Biotechnol. 2011 Dec;12(12):2081-98. Review.


Mitochondrion-dependent N-terminal processing of outer membrane Mcl-1 protein removes an essential Mule/Lasu1 protein-binding site.

Warr MR, Mills JR, Nguyen M, Lemaire-Ewing S, Baardsnes J, Sun KL, Malina A, Young JC, Jeyaraju DV, O'Connor-McCourt M, Pellegrini L, Pelletier J, Shore GC.

J Biol Chem. 2011 Jul 15;286(28):25098-107. doi: 10.1074/jbc.M111.218321. Epub 2011 May 25.


Identification of vascular breast tumor markers by laser capture microdissection and label-free LC-MS.

Hill JJ, Tremblay TL, Pen A, Li J, Robotham AC, Lenferink AE, Wang E, O'Connor-McCourt M, Kelly JF.

J Proteome Res. 2011 May 6;10(5):2479-93. doi: 10.1021/pr101267k. Epub 2011 Apr 1.


Identification of high-quality cancer prognostic markers and metastasis network modules.

Li J, Lenferink AE, Deng Y, Collins C, Cui Q, Purisima EO, O'Connor-McCourt MD, Wang E.

Nat Commun. 2010 Jul 13;1:34. doi: 10.1038/ncomms1033. Erratum in: Nat Commun. 2012;3. doi:10.1038/ncomms1033.


Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours.

Iqbal U, Trojahn U, Albaghdadi H, Zhang J, O'Connor-McCourt M, Stanimirovic D, Tomanek B, Sutherland G, Abulrob A.

Br J Pharmacol. 2010 Jun;160(4):1016-28. doi: 10.1111/j.1476-5381.2010.00742.x.


Structural basis of the regulation of the CbpA co-chaperone by its specific modulator CbpM.

Sarraf NS, Baardsnes J, Cheng J, O'Connor-McCourt M, Cygler M, Ekiel I.

J Mol Biol. 2010 Apr 23;398(1):111-21. doi: 10.1016/j.jmb.2010.03.006. Epub 2010 Mar 10.


A multi-strategy approach to informative gene identification from gene expression data.

Liu Z, Phan S, Famili F, Pan Y, Lenferink AE, Cantin C, Collins C, O'Connor-McCourt MD.

J Bioinform Comput Biol. 2010 Feb;8(1):19-38.


Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies.

Lenferink AE, Cantin C, Nantel A, Wang E, Durocher Y, Banville M, Paul-Roc B, Marcil A, Wilson MR, O'Connor-McCourt MD.

Oncogene. 2010 Feb 11;29(6):831-44. doi: 10.1038/onc.2009.399. Epub 2009 Nov 23.


Differential tumor-targeting abilities of three single-domain antibody formats.

Bell A, Wang ZJ, Arbabi-Ghahroudi M, Chang TA, Durocher Y, Trojahn U, Baardsnes J, Jaramillo ML, Li S, Baral TN, O'Connor-McCourt M, Mackenzie R, Zhang J.

Cancer Lett. 2010 Mar 1;289(1):81-90. doi: 10.1016/j.canlet.2009.08.003. Epub 2009 Aug 28.


The extracellular domain of the TGFbeta type II receptor regulates membrane raft partitioning.

Luga V, McLean S, Le Roy C, O'Connor-McCourt M, Wrana JL, Di Guglielmo GM.

Biochem J. 2009 Jun 12;421(1):119-31. doi: 10.1042/BJ20081131.


Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

Aguilar-Mahecha A, Cantin C, O'Connor-McCourt M, Nantel A, Basik M.

Proteome Sci. 2009 Apr 6;7:15. doi: 10.1186/1477-5956-7-15.


TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs.

Baardsnes J, Hinck CS, Hinck AP, O'Connor-McCourt MD.

Biochemistry. 2009 Mar 17;48(10):2146-55. doi: 10.1021/bi8019004.


Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition.

Hill JJ, Tremblay TL, Cantin C, O'Connor-McCourt M, Kelly JF, Lenferink AE.

Proteome Sci. 2009 Jan 8;7:2. doi: 10.1186/1477-5956-7-2.


Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.

Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, Siegel PM.

Oncogene. 2009 Feb 19;28(7):1005-15. doi: 10.1038/onc.2008.454. Epub 2008 Dec 15.


Escherichia coli expression and refolding of E/K-coil-tagged EGF generates fully bioactive EGF for diverse applications.

Le PU, Lenferink AE, Pinard M, Baardsnes J, Massie B, O'Connor-McCourt MD.

Protein Expr Purif. 2009 Apr;64(2):108-17. doi: 10.1016/j.pep.2008.11.005. Epub 2008 Nov 25.


Analysis of the contribution of receptor subdomains to the cooperative binding and internalization of transforming growth factor-beta (TGF-beta) type I and type II receptors.

Zwaagstra JC, Collins C, Langlois MJ, O'Connor-McCourt MD.

Exp Cell Res. 2008 Aug 15;314(14):2553-68. doi: 10.1016/j.yexcr.2008.06.012. Epub 2008 Jun 19.


The crystal structure and dimerization interface of GADD45gamma.

Schrag JD, Jiralerspong S, Banville M, Jaramillo ML, O'Connor-McCourt MD.

Proc Natl Acad Sci U S A. 2008 May 6;105(18):6566-71. doi: 10.1073/pnas.0800086105. Epub 2008 Apr 29.


Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors.

Jaramillo ML, Banville M, Collins C, Paul-Roc B, Bourget L, O'Connor-McCourt M.

Cancer Biol Ther. 2008 Apr;7(4):557-68. Epub 2008 Jan 7.


A ligand-pseudoreceptor system based on de novo designed peptides for the generation of adenoviral vectors with altered tropism.

Zeng Y, Pinard M, Jaime J, Bourget L, Uyen Le P, O'Connor-McCourt MD, Gilbert R, Massie B.

J Gene Med. 2008 Apr;10(4):355-67. doi: 10.1002/jgm.1155.


A map of human cancer signaling.

Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, Yang S, Zhang S, Liu L, Lu M, O'Connor-McCourt M, Purisima EO, Wang E.

Mol Syst Biol. 2007;3:152. Epub 2007 Dec 18.


Cancer systems biology: exploring cancer-associated genes on cellular networks.

Wang E, Lenferink A, O'Connor-McCourt M.

Cell Mol Life Sci. 2007 Jul;64(14):1752-62. Review.


Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.

Jaramillo ML, Leon Z, Grothe S, Paul-Roc B, Abulrob A, O'Connor McCourt M.

Exp Cell Res. 2006 Sep 10;312(15):2778-90. Epub 2006 May 23.


Adenovirus-delivered antisense RNA and shRNA exhibit different silencing efficiencies for the endogenous transforming growth factor-beta (TGF-beta) type II receptor.

Ogorelkova M, Zwaagstra J, Elahi SM, Dias C, Guilbaut C, Lo R, Collins C, Jaramillo M, Mullick A, O'Connor-McCourt M, Massie B.

Oligonucleotides. 2006 Spring;16(1):2-14.


Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor.

De Crescenzo G, Hinck CS, Shu Z, Zúñiga J, Yang J, Tang Y, Baardsnes J, Mendoza V, Sun L, López-Casillas F, O'Connor-McCourt M, Hinck AP.

J Mol Biol. 2006 Jan 6;355(1):47-62. Epub 2005 Nov 2. Erratum in: J Mol Biol. 2006 Jun 2;359(2):508.


Enhancement of the antagonistic potency of transforming growth factor-beta receptor extracellular domains by coiled coil-induced homo- and heterodimerization.

De Crescenzo G, Pham PL, Durocher Y, Chao H, O'Connor-McCourt MD.

J Biol Chem. 2004 Jun 18;279(25):26013-8. Epub 2004 Mar 24.


Link protein has greater affinity for versican than aggrecan.

Shi S, Grothe S, Zhang Y, O'Connor-McCourt MD, Poole AR, Roughley PJ, Mort JS.

J Biol Chem. 2004 Mar 26;279(13):12060-6. Epub 2004 Jan 14.


Structural basis of ligand recognition by PABC, a highly specific peptide-binding domain found in poly(A)-binding protein and a HECT ubiquitin ligase.

Kozlov G, De Crescenzo G, Lim NS, Siddiqui N, Fantus D, Kahvejian A, Trempe JF, Elias D, Ekiel I, Sonenberg N, O'Connor-McCourt M, Gehring K.

EMBO J. 2004 Jan 28;23(2):272-81. Epub 2003 Dec 18.


Expression of TGF-beta type II receptor antisense RNA impairs TGF-beta signaling in vitro and promotes mammary gland differentiation in vivo.

Lenferink AE, Magoon J, Pepin MC, Guimond A, O'Connor-McCourt MD.

Int J Cancer. 2003 Dec 20;107(6):919-28.


Substrate cleavage by caspases generates protein fragments with Smac/Diablo-like activities.

Hell K, Saleh M, Crescenzo GD, O'Connor-McCourt MD, Nicholson DW.

Cell Death Differ. 2003 Nov;10(11):1234-9.


A direct interaction between transforming growth factor (TGF)-betas and amyloid-beta protein affects fibrillogenesis in a TGF-beta receptor-independent manner.

Mousseau DD, Chapelsky S, De Crescenzo G, Kirkitadze MD, Magoon J, Inoue S, Teplow DB, O'Connor-McCourt MD.

J Biol Chem. 2003 Oct 3;278(40):38715-22. Epub 2003 Jul 16.


Supplemental Content

Loading ...
Support Center